A review by the U.S. Food and Drug Administration (FDA) has found that
the AstraZeneca Plc’s diabetes drug, Onglyza, may be associated
with an increased rate of death.
A trial was underway of more than 16,000 patients taking Onglyza. It has
been reported that these patients had an increased risk of hospital visits
due to heart failure.
The personal injury attorneys at Williams DeClark Tuschman will continue
to monitor this as more news unfolds. In the mean time, should you have
any questions regarding Onglyza, please call our office at 419-241-7700.
We are more than happy to answer any questions you have.